Form 4 Filing for ACADIA PHARMACEUTICALS INC

This filing details transactions by director Edmund Harrigan on May 29, 2026. Harrigan acquired 8,107 shares of Common Stock under a non-derivative transaction (Code M, Acquired A) with a post-transaction holding of 43,148 shares. In derivative transactions, 8,107 Restricted Stock Units were disposed of (Code M, Disposed D), with vesting detailed in footnotes. Additionally, 16,004 Director Stock Options (Right to Buy) were acquired (Code A, Acquired A), resulting in 16,004 shares held post-transaction. Another 9,311 Restricted Stock Units were acquired (Code A, Acquired A), with 9,311 shares held post-transaction. These transactions were reported on a Form 4 filing with the SEC.